|
|
News Breaks | | | | March 7, 2013 | | 08:18 EDT |  | CELG | Celgene and Acceleron initiate Phase 2 study of ACE-536
Acceleron Pharma initiated a phase 2 study of its novel, investigational protein therapeutic, ACE-536, which is being developed by Acceleron as part of a global collaboration with Celgene, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart. This is the second ongoing Phase 2 trial for ACE-536. | |
|
News For CELG From The Last 14 Days Check below for free stories on CELG the last two weeks. |
|
|
| May 23, 2013 | | 07:37 EDT | | CELG | Celgene says FDA grants priority review for ABRAXANE sNDA
 Subscribe for More Information | | | May 20, 2013 | | 09:51 EDT |  | CELG | Celgene management to meet with JPMorgan
Meetings to be held in Boston on May 22-23 hosted by JPMorgan. | | | May 17, 2013 | | 05:51 EDT |  | CELG | Stocks with implied volatility movement; CBST CELG
Subscribe for More Information | | | May 16, 2013 | | 11:50 EDT | | CELG | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | |
|
|
|
|
|
|
